

## Are we ready for the next pandemic?

COVID-19 arrived and suddenly governments, business and the world population faced a wide range of challenges simultaneously, from controlling the virus to keep the economy going.

Although we are not over the current pandemic, we can't afford not to be ready to face the next global health challenge.

### *Part 1. Anticipating future scenarios*

Anticipating future scenarios from a public health perspective and developing policies to detect, isolate and treat infectious diseases is a must if, as the covid-19 pandemic has taught us, we want to mitigate its impact.

As it is likely that this will not be the last or worse pandemic, we will discuss in this panel what are the most likely global health issues, from new viruses to antibiotic resistance bacteria and new tropical diseases due to climate change, and what policies are being implemented to coordinate a local and global response.

### **Moderator:**

**TBA**

### **Speakers:**

**Antonio Lopez Navas**, Spain's National Plan Against Antibiotic Resistance-PRAN AEMPS, Spain

**Other speakers TBA soon.**

## ***Part 2. Biotech solutions for an effective response***

As we will discuss in part-1 of this session, public policies are a key factor to anticipate future scenarios for the next global health crisis.

An essential part of these strategies & policies includes private-public partnerships, as governments alone are not equipped to offer the expertise, services and innovative solutions required. As we all know, this collaboration resulted in the development, approval, and manufacturing of a wide range of vaccines to stop covid-19 and slowly come back to normality.

How the biotech industry is preparing to face future challenges such as future infectious diseases, bacteria resistance or tropical diseases will be key to deliver an effective response that saves millions of lives.

### **Moderator:**

**TBA**

### **Speakers:**

**Alexander (Sandy) Douglas**, Research Group Leader at the University of Oxford, UK

**Juanjo Infante**, CEO, Vaxdyn, Spain

**Damaso Molero**, CEO, 3P Bio, Spain